AstraZeneca

Financial Performance Investment Vaccine Development Investments Technology Advancements Research and Development Investment Decisions Acquisition Merger Vaccine Work Costs Growth Strategy Vaccine Withdrawal US Market Production Corporate Strategy Market Strategy Innovation Revenue Growth Products New Medicines Expansion

9 ARTICLES

5mo ago

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

Robust double-digit profit growth spurred a reassessment of a U.S. primary listing to strengthen its presence in the world’s largest biopharmaceutical market.